HCT/p Amniotic Allograft Therapeutic Joint Injection products do not require fetal sacrifice and recovery is performed with maternal consent during live birth. Placental tissues are collected at several facilities around the country, following strict guidelines and consistent with industry best practices.

Donors are healthy women between the ages of 18-45 years. A careful medical and social history is collected in advance to ensure mothers meet all eligibility requirements. Donors are thoroughly screened for communicable diseases.

At the time of Cesarean delivery (also known as C-section), the baby is delivered and the placenta and fluid, which are typically discarded, are saved. All tissues are then tested to ensure viability and safety.

Tissues are processed to the highest standards in a state-of-the-art American Association of Tissue Banks (AATB) accredited facility and allografts are subjected to stringent USP testing prior to release.

HCT/p Amniotic Allograft Therapeutic Joint Injection products may not provide an improvement in your condition or injury. There is a possibility of an adverse immune reaction.

This is not a complete list of risks. Discuss the potential risks and benefits of product use with your doctor or health professional.

Recovery time can vary, but in most cases it’s zero. Most of our patients can resume their daily work activities immediately after the treatment.

For most patients, the treatment is almost completely painless and they are able to get back to doing what they need to in no time at all.